Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home News Macro

Trump Signs Executive Order to Lower Drug Prices and Address Medicare Policies

by Team Lumida
April 16, 2025
in Macro
Reading Time: 5 mins read
A A
0
$500 Billion Stargate AI Project Announcement Raises Funding Questions
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways:

Powered by lumidawealth.com

  • President Trump signed an executive order aimed at reducing prescription drug prices, reviving policies from his first term, such as discounted insulin and epinephrine for uninsured and low-income patients at community health centers.
  • The order directs the Department of Health and Human Services (HHS) to address the “pill penalty” in the Inflation Reduction Act, which makes pills eligible for Medicare price negotiations after nine years, compared to 13 years for injected drugs.
  • The FDA has been instructed to streamline the drug importation program, initially introduced during Trump’s first term, to allow states to import lower-cost drugs more efficiently.
  • Trump also signed a memorandum to expand the Social Security Administration’s fraud prosecution program to prevent ineligible payments.

What Happened?

President Trump signed an executive order on Tuesday to lower prescription drug prices, focusing on Medicare beneficiaries and uninsured Americans. The order revives policies from his first administration, including a mandate for community health centers to provide discounted insulin and injectable epinephrine. This rule, rescinded by the Biden administration in 2021, is now back in effect.

The order also addresses the “pill penalty” in the Inflation Reduction Act, which has been criticized by the pharmaceutical industry for discouraging the development of pills. Pills become eligible for Medicare price negotiations after nine years on the market, while injected drugs have a 13-year timeline. The order directs HHS Secretary Robert F. Kennedy Jr. to work with Congress to equalize these timelines.

Additionally, the order calls for the FDA to streamline the drug importation program, which allows states to import lower-cost drugs under certain conditions. Florida is currently the only state with an approved program, but the order aims to make it easier for other states to gain approval.


Why It Matters?

The executive order reflects Trump’s ongoing focus on making prescription drugs more affordable, an issue that resonates with many Americans who believe drug prices are too high. By reviving policies like discounted insulin and addressing the “pill penalty,” the administration aims to reduce healthcare costs and encourage pharmaceutical innovation.

The streamlined drug importation program could provide states with access to lower-cost medications, potentially easing the financial burden on consumers. However, the success of these initiatives will depend on congressional action and the FDA’s ability to implement the changes effectively.

The expansion of the Social Security Administration’s fraud prosecution program also signals a broader effort to improve government efficiency and reduce wasteful spending.


What’s Next?

HHS will work with Congress to address the “pill penalty” and modify the Inflation Reduction Act, though legislative changes may face resistance from the pharmaceutical industry. The FDA will also need to act quickly to simplify the drug importation process and approve more state programs.

The broader impact of these measures on drug prices and healthcare costs will depend on how effectively they are implemented and whether Congress supports the proposed changes. Meanwhile, the Social Security Administration will ramp up efforts to prevent fraud and ensure benefits are distributed appropriately.

Source
Previous Post

J.B. Hunt Profit Drops Amid Weak Freight Demand and Tariff Uncertainty

Next Post

United Airlines Beats Expectations Despite Travel Demand Concerns and Economic Uncertainty

Recommended For You

IMF’s Georgieva Says the World Economy Is ‘Standing on One Leg’ of AI as Circular Financing Tops $1 Trillion, Two-Thirds Funded by Debt

by Team Lumida
8 hours ago
Dimon Says AI Cyber Risk Rose Tenfold After Mythos, While Declining to Engage With the Existential Question

IMF chief Georgieva warned that circular AI financing has topped $1 trillion, mostly debt-funded, leaving the global economy reliant on AI.

Read more

10-Year Treasury Yield Eases to 5.131% From Friday’s 5.174% High as Investors Await Warsh’s Remarks on AI, Productivity and Jobs

by Team Lumida
8 hours ago
KKR Lifts Its 10-Year Treasury Call to 5.1% and Pushes the Fed Hold Out to Early 2029

Treasury yields dipped Monday, with the 10-year at 5.131%, as investors awaited Fed Chair Warsh and a week of retail sales data and FOMC minutes.

Read more

Bessent Says Treasury, Defense and State Backed Blacklisting Megaspeed ‘for Months,’ and Blames Commerce for Nvidia Chip ‘Leakage’

by Team Lumida
3 days ago

Treasury Secretary Bessent said several departments backed blacklisting Megaspeed for months, and he called Nvidia chip leakage to China “very frustrating.”

Read more

October PPI Rises 0.3%, but the Annual Rate Hits 6.5%, the Highest Since November 2022, as Goolsbee Says the Fed Has ‘Work to Do’

by Team Lumida
3 days ago

October PPI rose 0.3%, but the annual rate hit 6.5%, a nearly four-year high, as Chicago Fed President Goolsbee said the Fed has work to do.

Read more

10-Year Treasury Yield Hits 5.174% After the PPI Report, as Traders Price a December Fed Hike as a Certainty

by Team Lumida
3 days ago

The 10-year Treasury yield reached 5.174% on Friday and was at 5.143%, as traders priced 100% odds of a Federal Reserve rate increase on Dec. 9.

Read more

87% of Fed Survey Respondents Now Cite AI as a Salient Financial-System Risk, Up From 50% in the Spring

by Team Lumida
3 days ago

A Federal Reserve survey released Friday found 87% of respondents cited AI as a salient risk to the financial system, up from 50% in the spring.

Read more

10-Year Treasury Yield Edges Up 2 Basis Points to 5.01% as Cash Bond Trading Resumes After Veterans Day

by Team Lumida
5 days ago

The 10-year Treasury yield rose 2 basis points to 5.01% as cash bond trading resumed after Veterans Day, with PPI and home sales due.

Read more

Huang’s Scandal Revives a Push to Put New China Chip Curbs in the NDAA Ahead of Next Week’s Trump-Xi Summit

by Team Lumida
5 days ago

Huang’s scandal is reviving a push to put new China chip curbs in this year’s defense bill, days before a planned Trump-Xi meeting.

Read more

Goolsbee Calls October CPI ‘Borderline Disturbing’ and Puts Everything ‘on the Table,’ While Voter Paulson Says Only Gradual Fed Tightening Is Needed for Now

by Team Lumida
6 days ago

Goolsbee called October’s CPI ‘borderline disturbing,’ while Philadelphia Fed voter Paulson said gradual tightening still seems appropriate for now.

Read more

US Credit Card Balances Hit a Record $1.29 Trillion as Growth Slows to 4.2% and Serious Delinquencies Hold Near 12.9%, New York Fed Says

by Team Lumida
6 days ago
US Credit Card Defaults Surge to Post-2008 Highs, Signaling Consumer Stress

Credit card balances rose 4.2% to a record $1.29 trillion in the third quarter as household debt hit $19.1 trillion, while card delinquencies steadied.

Read more
Next Post
a united airlines plane flying in the sky

United Airlines Beats Expectations Despite Travel Demand Concerns and Economic Uncertainty

Nvidia’s AI Demand Surge: Hon Hai Ramps Up Server Production

Nvidia Warns $5.5 Billion Loss as Trump Bans AI Chip Sales to China

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Related News

a computer chip with the letter a on top of it

AI Costs Skyrocket: Investors Pivot to Leaner Data Strategies

August 8, 2024
Ilya Sutskever Unveils New AI Startup Focused on Superintelligent Safety

Ilya Sutskever Unveils New AI Startup Focused on Superintelligent Safety

June 20, 2024
a group of rings

Bitcoin Could Swing $5K After White House Crypto Summit, ETH and SOL Volatility Expected

March 6, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Legacy
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Opinions
    • Investing Philosophy
    • Op-Ed
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Investing Philosophy
  • Latest
  • Legacy
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Op-Ed
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips Amazon Apple Artificial Intelligence Banking Bank of America China Commercial Real Estate CPI data centers Donald Trump EARNINGS ELON MUSK Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Novo Nordisk Nuclear Energy Nvidia oil OpenAI private equity S&P 500 SEC Semiconductor stock market stock surge Tech Stocks tesla Trump Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018